S. Matthews
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Psoriasis: Treatment and Pathogenesis, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Peptidase Inhibition and Analysis
Most-Cited Works
- → Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)(2006)114 cited
- → Catalytic Determinants of Alkene Production by the Cytochrome P450 Peroxygenase OleTJE(2017)104 cited
- → A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial(2006)83 cited
- → The 2016 Melbourne thunderstorm asthma epidemic: Risk factors for severe attacks requiring hospital admission(2018)80 cited
- → Production of alkenes and novel secondary products by P450 OleTJE using novel H2O2‐generating fusion protein systems(2017)79 cited
- → National Audit of the Management and Outcome of Carcinoma of the Cervix Treated with Radiotherapy in 1993(2000)78 cited
- → Evaluation of Weight Loss Over Time in Cats with Chronic Kidney Disease(2016)77 cited
- → Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115(2006)70 cited
- → A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer(2005)67 cited
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.(2003)